Biologic medicines (also known as ‘biologics’) are large complex molecules (proteins, antibodies or similar molecules) that exert their effect by interaction with biologic processes, which they may augment or inhibit.
Biosimilars are biologics which have a similar action to originator products, but are usually marketed at a lower price than the originator product. This series of publications are intended to support the introduction of biosimilars into clinical use.
Topics published so far:
|
Subject |
Date |
Link |
| Biosimilars - new developments (Infliximab) |
Jan 15 |
Link |
| Biosimilars- new insulin glargine |
Sept 15 |
Link |
|
|
|
|
|
|
|
|